Development of a novel android mobile phone application for Diabetes Type II syndrome by using Molecular modelling through Virtual Screening and Molecular docking tool - a Molecular level medical data mining approach

Dr M.Subas Chandra Bose

Abstract


Android and iPhones are the two most popular mobile devices today. Each of these mobile Operating System is constantly trying to surpass the other, both in terms of the software developer and the user. While each one is just as powerful as another one, they are not without their own exceptional disadvantages. In this article, we analyze the pros and cons of both Android and iPhone from the point of view of medical applications of developers and medical researchers. Intravenous glucose tolerance level are called as Diabetes mellitus syndrome which is a group of metabolic disorder disease resulting in increased blood sugar level, either because of the pancreas will not able to secrete enough insulin as fluid or because human cells will not respond or revert to the insulin produced in human body. The Diabetes mellitus type 2 (NIDDM) is a human metabolic disorder and which is characterized by the high glucose contend in the blood on context of the body insulin resistance as well as deficiency in the human body.Over the past few decades, the human receptors of nuclear family, in particular the activated receptors of peroxisome proliferator (PPARs), has emerged as one of the most important drug targets the metabolic syndrome.Consequently, compounds that activate the PPARs have served as a potential therapeutics for the treatment of T2DM and anomalities associated with this disorder. The present investigation has been designed with a focus to identify novel ligands using TZDs that could facilitate the drug action for T2DM. These identified ligands can be interrogated by using the developed app through android phone


Full Text:

PDF

References


Alarcón de la Lastra C, Sánchez-Fidalgo S, Villegas I, Motilva V(2004). „New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists‟, J. Curr Pharm Des.,Vol.10(28), pp. 3505-3524.

Berger J, Moller DE Annu (2002). „The mechanisms of action of PPARs‟, Rev. Med, Vol.53, pp. 409–425.

Bong-Soo Cha, Theodore P. Ciaraldi, Kyong-Soo Park, Leslie Carter, Sunder R. Mudaliar, and Robert R. Henry (2005). „Impaired fatty acid

metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARγagonists‟,Am. J. PhysiolEndocrinolMetab, Vol.289, pp. E151–E159.

DarkoButina, Matthew D Segall, Katrina Frankcombe (2002). „Predicting ADME properties – In silico methods and models‟, Drug Discovery Today, Elsevier, Vol.7 (11), pp. s83-s88.

E.F. Pettersen, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004).‟UCSF Chimera--a visualization system for exploratory research and analysis‟, J. Comput Chem., Vol. 25(13), pp. 1605-1612.

Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006).„From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions‟. Prog. Lipid Res. Vol. 45 (2) ,pp. 120–59.

H.H. Parekh, K.A. Parikh, and A.R. Parikh(2004).‟Synthesis of Some 4-Thiazolidinone Derivatives as AntitubercularAgents.J.Sciences‟, Islamic Republic of Iran,Vol.15(2), pp 143-148.

Ha-il Kim and Yong-hoAhn(2004).‟Role of Peroxisome Proliferator–Activated Receptor- in the Glucose-Sensing Apparatus of Liver and β-Cells‟. Diabetes, Vol. 53(2), pp.60-65.

Hebe N. Gouda, Gurdeep S. Sagoo, Anne-Helen Harding, Jan Yates, Manjinder S. Sandhu, and Julian P. T. Higgins (2009).‟The Association Between the Peroxisome Proliferator-Activated Receptor-g2 (PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes Mellitus‟, A HuGE Review and Meta-Analysis.Am. J. Epidemiology.,Vol.171, pp. 645-655.

HolgerGohlke, Manfred Hendlich and Gerhard Klebe(2000).‟Knowledge based scoring function to predict protein ligand interactions‟, J.Mol.Biol., Vol. 295, pp. 337-356.


Refbacks

  • There are currently no refbacks.